EGFR and cancer: EGFR, which is frequently mutated or overexpressed in cancer, was found to be amplified in 2/10 (20%) DSRCT tumors (41), and an EGFR CAR T cell trial for children and young adults with refractory/recurrent solid tumors (including DSRCT) is currently underway (NCT03618381).